| |
Patients (n = 107)
|
Numbers (%)
|
|---|
|
Age (years)
|
Mean ± SD
|
6.0 ± 3.1
|
|
Median (range)
|
5.3 (1.3–17.4)
|
|
Gender
|
Male
|
62 (57.9)
|
|
Female
|
45 (42.1)
|
|
Region
|
Central
|
45 (42.1)
|
|
Northeast
|
41 (38.3)
|
|
South
|
21 (19.6)
|
|
Health care system
|
University-based
|
81 (75.7)
|
|
Community-based
|
26 (24.3)
|
|
Primary tumor site
|
Adrenal
|
88 (82.2)
|
|
Abdominal
|
4 (3.7)
|
|
Thoracic
|
7 (6.5)
|
|
Others
|
8 (7.5)
|
|
Metastatic site at diagnosis
|
Bone marrow
|
69 (64.5)
|
|
Bone
|
66 (61.7)
|
|
Lymph node
|
41 (38.3)
|
|
Liver
|
14 (13.1)
|
|
Brain
|
3 (2.8)
|
|
Others
|
7 (6.5)
|
|
Serum NSE (n = 82)
|
Mean ± SD
|
455.4 ± 412.9
|
|
Median (range)
|
370.0 (0–2180.0)
|
|
Urine VMA (n = 86)
|
Mean ± SD
|
38.2 ± 70.1
|
|
Median (range)
|
18.9 (0–494.0)
|
|
INRG Stage
|
Stage M
|
106 (99.0)
|
|
Stage L2 (with MYCN amplification)
|
1 (1.0)
|
-
Notes: Data are presented as mean ± SD and median (range) for continuous variables and number (%) for categorical variables
- Abbreviations: NSE serum neuron-specific enolase (ng/mL); VMA urine vanillylmandelic acid (mg/day); Stage M distant metastatic disease (except stage MS); Stage L2 locoregional tumor with presence of one or more image-defined risk factors
